Evidence map›Paper›PMID 39652169›Full record

ReviewAnnals of hematology2024

Advances in epigenetic therapies for B-cell non-hodgkin lymphoma.

Weiwen Hu, Lanlan Zang, Xiaoxi Feng, Shuhui Zhuang, Liudi Chang, Yongjing Liu, Jinyan Huang, Yuanyuan Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weiwen HuSchool of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Lanlan ZangPharmaceutical laboratory, Department of Pharmacy, Linyi People's Hospital, Shandong Second Medical University, Linyi, 276000, Shandong, China.
Xiaoxi FengSchool of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Shuhui ZhuangSchool of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Liudi ChangSchool of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Yongjing LiuBiomedical Big Data Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 311121, China. coy@zju.edu.cn.
Jinyan HuangBiomedical Big Data Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 311121, China. huangjinyan@zju.edu.cn.
Yuanyuan ZhangDepartment of Hematology, Linyi People's Hospital, Shandong Second Medical University, Linyi, 276000, Shandong, China. doctorzhangyy@163.com.

Funding

Linyi People's Hospital Doctoral Fund Project 2016LYBS13Medical and Health Science and Technology Development Project of Shandong Province 2017WS133Shandong Key Laboratory on Hematoimmunology Open project 2019XYKF009Shandong Provincial Natural Science Foundation ZR2018PH014Shandong Provincial Postdoctoral Innovation Project 201903077Shandong Traditional Chinese Medicine Science and Technology Development Plan Project 2017-472Xuzhou Medical University Affiliated Hospital Development Fund Project XYFM20200031
6 · The paper itself

Abstract

B-cell non-Hodgkin lymphomas (B-NHLs) constitute a varied group of cancers originating from B lymphocytes. B-NHLs can occur at any stage of normal B-cell development, with most arising from germinal centres (e.g. diffuse large B-cell lymphoma, DLBCL and follicular lymphoma, FL). The standard initial treatment usually involves the chemoimmunotherapy regimen. Although there is a high initial response rate, 30-40% of high-risk patients often face relapsed or refractory lymphoma due to drug resistance. Recent research has uncovered a significant link between the development of B-NHLs and various epigenetic processes, such as DNA methylation, histone modification, regulation by non-coding RNAs, and chromatin remodeling. Therapies targeting these epigenetic changes have demonstrated considerable potential in clinical studies. This article examines the influence of epigenetic regulation on the onset and progression of B-NHLs. It discusses the current therapeutic targets and agents linked to these epigenetic mechanisms, with the goal of offering new perspectives and approaches for targeted therapies and combination chemotherapy in treating B-NHLs.

Indexed as

Epigenesis, GeneticLymphoma, B-CellDNA MethylationHumansMolecular Targeted TherapyB-NHLsEpigenetic drugsEpigeneticsTargeted therapy

Identifiers

PMID39652169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.